MEDP Stock Recent News

Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Medpace delivered a stunning Q2 2025, with double-digit revenue and net new awards growth, defying widespread healthcare sector pessimism. The company achieved 14% YoY revenue growth and 18.6% EBITDA growth, far surpassing expectations, and increased guidance for the year. Management accelerated opportunistic share buybacks, returning $908 million to shareholders in the first half of 2025, demonstrating exceptional capital allocation.

After reaching an important support level, Medpace Holdings, Inc. (MEDP) could be a good stock pick from a technical perspective. MEDP recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

Medpace (MEDP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

CALX, MEDP and WST made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 28, 2025.

MEDP, CBFV, CALX, TREE and HAS have been added to the Zacks Rank #1 (Strong Buy) List on July 28, 2025.

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Medpace (MEDP 54.51%), a clinical contract research organization that manages drug development for pharmaceutical and biotech clients, reported its second quarter 2025 earnings on July 17, 2025. The company delivered GAAP results that topped both earnings and revenue forecasts, with GAAP revenue of $603.3 million versus the estimated $538.8 million and GAAP earnings per share (EPS) of $3.10 versus the expected $2.98.

Medpace Holdings, Inc. (NASDAQ:MEDP ) Q2 2025 Earnings Conference Call July 22, 2025 9:00 AM ET Company Participants August James Troendle - Chairman & CEO Jesse J. Geiger - President Kevin M.

Medpace's Global CRO Reach Lends Credibility For Its 2025 Revenue Guidance Increase